Skip to main content Accessibility help
×
Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-09T08:45:35.892Z Has data issue: false hasContentIssue false

2 - From pharmacogenetics to pharmacogenomics of psychotropic drug response

from Part II - Clinical background and research design

Published online by Cambridge University Press:  20 August 2009

Anil K. Malhotra
Affiliation:
Hillside Hospital, Glen Oaks, New York
Bernard Lerer
Affiliation:
Hadassah-Hebrew Medical Center, Jerusalem
Get access

Summary

OVERVIEW

The marked interindividual variation in response to psychotropic drugs creates a clinical dilemma that can only be resolved through often lengthy empirical drug trials. Recent developments in molecular biology have provided an opportunity to identify molecular genetic predictors of drug response, which may have immediate clinical implications as well as provide critical data for future drug development. In this chapter, we will discuss the evidence for a heritable component to psychotropic drug response, review basic methodological issues in pharmacogenetic studies of psychotropic drug response, and then highlight future directions for pharmacogenetics research in psychiatry.

Introduction

Individual differences in clinical response to psychotropic drugs has long been recognized as a fundamental problem in the treatment of the seriously mentally ill patient. This variability in individual response ranges from patients who experience complete symptom remission to a subset of patients often described as “treatment refractory,” as well as a marked variability in susceptibility to adverse drug effects. A priori identification of the patients who will respond well to a particular psychotropic drug, or be at a higher risk for development of adverse side effects, has the potential to help clinicians to avoid lengthy ineffective medication trials and to limit a patient's exposure to drug side effects. Moreover, enhanced predictability of treatment response early in the course of a patient's illness may result in enhanced patient compliance and willingness to seek treatment rapidly upon symptom exacerbation or recurrence.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×